You may be able to reduce tardive dyskinesia with treatment. Some lifestyle behaviors, like getting enough sleep and exercise, can help. Tardive dyskinesia is a side effect of neuroleptic or ...

Tardive dyskinesia is a medication-induced movement disorder that causes uncontrollable muscle movements in the face, neck, and limbs. Symptoms may continue even after stopping the medication. Tardive ...

Tardive dyskinesia causes involuntary movements in some people taking antipsychotic medications. Here’s what you need to know about this movement disorder. Antipsychotic medications are a mainstay of ...

Credit: Getty Images This patient fact sheet describes the medications that are known to induce tardive dyskinesia, its symptoms, and ways in which the disease state may be managed. Our easy-to-read ...

Medically reviewed by Nicholas R. Metrus, MD Tardive dyskinesia and dystonia are movement disorders with different causes and onset of symptoms.Treatment for both disorders may involve anticholinergic ...

—The exact pathology of tardive dyskinesia is still unclear, but the potential genetic factors these investigators have identified may enhance the understanding, treatment, and prevention of this ...

—These investigators examined more than 2 decades’ worth of de-identified electronic health records to learn more about why tardive dyskinesia is likely to be underreported and misdiagnosed in routine ...

Tardive dyskinesia is a common side effect caused by antipsychotic use. It is a neurological disorder characterized by involuntary, repetitive movements, often involving the face, mouth, tongue, and ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Kristin Weiland is a documentary film producer and writer with a background in crisis management and ethnographic research. She specializes in investigative and social impact documentary projects, and ...

A case report indicates that valbenazine may be an effective therapy for chorea-ballism associated with tardive dyskinesia. Valbenazine has therapeutic potential to improve chorea-ballism associated ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has confirmed its initial recommendation to not consider deutetrabenazine as a new active substance. In June this ...